Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Bryn Nelson, PhD  |  June 15, 2020

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Advocacy in a COVID-19 America

Ellen M. Gravallese, MD  |  June 15, 2020

These are truly extraordinary times. The COVID-19 pandemic has affected the rheumatology community, both providers and patients, in many ways, and our advocacy efforts are now more important than ever to ensure policymakers hear us and help address the issues facing our community. As with so many things during this pandemic, we are reimagining advocacy…

Ethics Forum: Medical Ethical Considerations for COVID-19

David Y. Chen, MD, PhD, & Eric J. Gapud, MD, PhD, on behalf of the ACR Committee for Ethics & Conflicts of Interest  |  June 8, 2020

Prescribing stewardship is just one ethical consideration facing rheumatologists during the COVID-19 pandemic.

Advocacy During a Pandemic: An Update from the Government Affairs Committee

Blair Solow, MD  |  June 5, 2020

Although the COVID-19 outbreak has shifted the focus and approach of advocacy efforts, ACR staff and the Government Affairs Committee continue to work on behalf of rheumatology providers and patients.

ACR Continues to Advocate Against Payer Mandates on Specialty Pharmacy Acquisition of In-Office Treatments

From the College  |  June 5, 2020

Despite efforts by the ACR and other organizations, Blue Cross Blue Shield of Tennessee has indicated that it will move forward with implementation of its specialty pharmacy acquisition mandate on July 1, 2020.

Influential Lancet Article on HCQ Retracted

Michael Erman  |  June 5, 2020

NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…

Are ANAs More Prevalent in the U.S. Now Than in the Past?

Arthritis & Rheumatology  |  May 28, 2020

According to a new study, the prevalence of anti-nuclear antibodies (ANAs), the most common biomarker of autoimmunity in the U.S., has increased considerably in recent years among adolescents aged 12–19 years, in both sexes (especially in men), older adults (age ≥50 years) and non-Hispanic whites…

RheumPAC Hosts Rep. Ami Bera (D-Calif.) for Virtual Discussion of ACR Legislative Priorities

From the College  |  May 20, 2020

Top RheumPAC donors attended a virtual legislative update and Q&A with Rep. Ami Bera (D-Calif.) shortly after the release of House Democrats’ $3 trillion coronavirus response plan.

AMA House of Delegates Meeting Postponed Due to COVID-19, Advocacy Efforts Continue

Kimberly Retzlaff  |  May 20, 2020

Due to the COVID-19 pandemic, the AMA House of Delegates meeting planned for June has been canceled, but the ACR’s delegation remains ready to advocate for both ongoing and new rheumatology issues, including patient protections in step therapy, prior authorization and expansion of telehealth.

Researchers Discuss Viability of Rheumatology Education During the COVID‐19 Pandemic

Arthritis & Rheumatology  |  May 15, 2020

In a matter of weeks, the COVID‑19 crisis has totally upended clinical medicine and the practice of rheumatology. Our old ways of seeing patients in person, precepting fellows in clinic or on the consult service, and leading in-person interactive teaching rounds are gone for now and possibly for good. But how can we replace these…

  • « Previous Page
  • 1
  • …
  • 57
  • 58
  • 59
  • 60
  • 61
  • …
  • 244
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences